Combination therapy with inhaled corticosteroids (ICS) and long-acting β2-agonists (LABA) remains the clinical cornerstone of asthma management. However, the therapeutic potential of both agents can be limited by their hydrophobicity, which favors entrapment within pulmonary mucus and recognition and clearance by alveolar macrophages. These biological barriers reduce drug availability at the target airway tissues, often necessitating higher doses or more frequent administrations to achieve clinical effect. The reported work addresses these delivery barriers by developing and systematically optimizing a liposomal formulation for the co-delivery of ciclesonide (CIC) and indacaterol maleate (IND) to enhance local bioavailability and therapeutic efficacy.
Multiple PEGylated lipids were evaluated to identify a surface modifier that would both stabilize the liposomes and improve pulmonary performance. The authors selected DSPE-PEG for two principal reasons: its amine functional group promotes increased encapsulation of IND via amine–phosphate interactions, and its 18-carbon (C18) acyl chain provided superior biocompatibility with macrophages when compared to shorter chain analogs (C14 and C16). The formulation incorporated DSPE-PEG at 15% molar content, which the investigators found to enable robust mucopenetration while promoting macrophage evasion. This PEGylation level was associated with an improved ex vivo relaxation effect of encapsulated IND relative to the drug solution, indicating functional enhancement of the bronchodilator activity through lipid nanoparticle delivery.
For the primary bilayer component, the team chose DLPC (1,2-dilauroyl-sn-glycero-3-phosphocholine) based on its degree of unsaturation. DLPC’s higher unsaturation (noted as two double bonds in the publication) was essential to achieve high encapsulation efficiencies for both hydrophobic payloads. Beyond encapsulation, DLPC-containing liposomes displayed improved epithelial cell uptake in vitro and enhanced ex vivo efficacy and potency of IND. These findings suggest that the acyl-chain unsaturation of the main phospholipid plays a key role in balancing payload retention with cellular interaction and release properties in the pulmonary environment.
The optimized formulation combined DLPC as the main phospholipid with 15% DSPE-PEG on the surface. This composition achieved high encapsulation efficiencies for both CIC and IND and demonstrated favorable interactions with pulmonary barriers in preclinical assays. Specifically, the DSPE-PEG-modified liposomes showed enhanced mucopenetration and reduced clearance by macrophages, outcomes that the authors relate to the PEGylation chemistry and acyl-chain length. In epithelial cell models, liposomes with DLPC exhibited efficient uptake, and ex vivo assays showed that liposomal IND produced greater airway relaxation than an equivalent IND solution. These data collectively indicate that lipid composition and surface chemistry were tuned to improve both delivery to target cells and functional pharmacodynamic effect.
Efficacy of the optimized co-encapsulated CIC/IND liposomes was evaluated in an ovalbumin (OVA)-induced murine model of asthma. Treatment with the liposomal formulation markedly attenuated airway hyperresponsiveness and suppressed the type 2 inflammatory cascade. The reported suppression encompassed upstream epithelial-derived alarmins, downstream inflammatory cytokines, and recruitment of inflammatory cells to the airways. These in vivo findings support the translational rationale that improving pulmonary delivery and local retention of ICS/LABA agents through lipid nanoparticles can materially reduce pathophysiologic features of allergic airway disease in a preclinical model.
An important observation reported by the authors is a potential dose-sparing effect achieved by liposomal encapsulation for both CIC and IND. By improving target-site availability via mucopenetration and macrophage evasion, the liposomal system may allow similar or greater therapeutic effect at lower nominal doses than non-encapsulated drug solutions. The authors suggest that efficient pulmonary delivery of ICS/LABA via lipid nanoparticles could represent a promising strategy for asthma management and may be applicable to other respiratory diseases that share similar delivery barriers.
The article focuses on formulation optimization and preclinical proof-of-concept. While it reports improvements across in vitro, ex vivo and an OVA-induced murine model, the report in PubMed does not present clinical trial data. Quantitative details of some experiments, such as exact encapsulation percentages, dose regimens in vivo, and full pharmacokinetic characterization, are contained in the original article text but are not fully reproduced in this summary. The authors indicate potential broader applicability of the lipid nanoparticle approach to other respiratory conditions, but direct evidence for diseases beyond the OVA model was not provided in the abstract.
Overall, the study demonstrates that targeted lipid selection (DLPC) and optimized PEGylation (DSPE-PEG at 15%) can overcome key pulmonary delivery barriers for hydrophobic ICS and LABA agents, yielding improved epithelial uptake, macrophage evasion, enhanced bronchodilator potency ex vivo, suppression of type 2 inflammation in vivo, and a potential dose-sparing benefit.